The results of our previous preclinical studies with Angpt1 variants and ABTAA have demonstrated that enhancing healthy angiogenesis, vascular integrity, and stability through Tie2 activation provides definitive benefits for treating vascular dysfunctional diseases such as ischemic retinopathy, wet-type aged macular degeneration, sepsis, and primary angle glaucoma, and for enhancing drug delivery through tumor vessel normalization16–19,29. The gene discussed is TEK; the disease is neoplasm.